| |
| . |
 24  1/2  |
|
|
|
Subject |
Hyundai Pharm, Enters Clinical Phase III for Levotuss CR Tablet |
Content |
Hyundai Pharm, Enters Clinical Phase III for Levotuss CR Tablet
Hyundai Pharm (President Yeong Hak Kim) announced that clinical phase III for Levotuss CR IND was submitted on 29th to Ministry of Food and Drug Safety.
Currently, Hyundai Pharm has established a strong position in the respiratory market with Levotuss, Rhinathiol, Surfolase, etc.
Levotuss CR Tablet is a product extending bioavailability of levodropizine which improved convenience in administration by changing its dosage. Levodropizine is the first product which is developed as a controlled release tablet in Korea.
On October 1999 in Korea,. Hyundai Pharm received approval for Levotuss syrup for the first time in Korea and developed Levotuss tablet 60mg for the first time in the world on November 2006 and received approval.
Hyundai Pharm is developing its own extended release technology and planning study for conducting clinical studies and sustaining bioavailability of the drug in animal studies.
Hyundia Pharm plans to receive approval and launch through Clinical Phase III studies and confirming its efficacy and safety.
|
Date |
2015-05-12 |
|
 |
 |
 |
|
